SG11202001074RA - Methods for treating muscular dystrophy - Google Patents

Methods for treating muscular dystrophy

Info

Publication number
SG11202001074RA
SG11202001074RA SG11202001074RA SG11202001074RA SG11202001074RA SG 11202001074R A SG11202001074R A SG 11202001074RA SG 11202001074R A SG11202001074R A SG 11202001074RA SG 11202001074R A SG11202001074R A SG 11202001074RA SG 11202001074R A SG11202001074R A SG 11202001074RA
Authority
SG
Singapore
Prior art keywords
methods
muscular dystrophy
treating muscular
treating
dystrophy
Prior art date
Application number
SG11202001074RA
Other languages
English (en)
Inventor
Edward M Kaye
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of SG11202001074RA publication Critical patent/SG11202001074RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/33Alteration of splicing
SG11202001074RA 2017-08-31 2018-08-31 Methods for treating muscular dystrophy SG11202001074RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762553094P 2017-08-31 2017-08-31
US201762565824P 2017-09-29 2017-09-29
US201862725129P 2018-08-30 2018-08-30
PCT/US2018/049151 WO2019046755A1 (fr) 2017-08-31 2018-08-31 Méthodes permettant de traiter la dystrophie musculaire

Publications (1)

Publication Number Publication Date
SG11202001074RA true SG11202001074RA (en) 2020-03-30

Family

ID=65526062

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001074RA SG11202001074RA (en) 2017-08-31 2018-08-31 Methods for treating muscular dystrophy

Country Status (15)

Country Link
US (1) US20230038956A1 (fr)
EP (1) EP3675836A4 (fr)
JP (2) JP2020532504A (fr)
KR (1) KR20200046069A (fr)
CN (1) CN111417388A (fr)
AR (1) AR112538A1 (fr)
AU (1) AU2018326780A1 (fr)
CA (1) CA3073736A1 (fr)
CO (1) CO2020004034A2 (fr)
IL (1) IL272791A (fr)
MA (1) MA50062A (fr)
MX (1) MX2020002038A (fr)
SG (1) SG11202001074RA (fr)
TW (1) TW201919655A (fr)
WO (1) WO2019046755A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US20220296633A1 (en) * 2019-06-19 2022-09-22 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
CN112430645A (zh) * 2020-12-09 2021-03-02 北京华瑞康源生物科技发展有限公司 一种多重实时荧光pcr法检测人dmd基因拷贝数的相对定量方法及试剂盒
WO2023168427A1 (fr) 2022-03-03 2023-09-07 Yale University Compositions et procédés d'administration de polynucléotides thérapeutiques pour saut d'exon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
HUE042218T2 (hu) * 2013-03-14 2019-06-28 Sarepta Therapeutics Inc Exonátugrást elõsegítõ készítmények izomdisztrófia kezelésére
BR112015022998A2 (pt) * 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
BR112018007066A2 (pt) * 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados

Also Published As

Publication number Publication date
MX2020002038A (es) 2020-09-18
CO2020004034A2 (es) 2020-04-24
JP2023138867A (ja) 2023-10-02
AR112538A1 (es) 2019-11-06
CA3073736A1 (fr) 2019-03-07
TW201919655A (zh) 2019-06-01
EP3675836A4 (fr) 2021-05-26
MA50062A (fr) 2020-07-08
AU2018326780A1 (en) 2020-02-27
IL272791A (en) 2020-04-30
WO2019046755A1 (fr) 2019-03-07
EP3675836A1 (fr) 2020-07-08
KR20200046069A (ko) 2020-05-06
JP2020532504A (ja) 2020-11-12
US20230038956A1 (en) 2023-02-09
CN111417388A (zh) 2020-07-14

Similar Documents

Publication Publication Date Title
ZA201706616B (en) Method for treating cancer
IL269371A (en) Treatment methods
HK1258823A1 (zh) 用於治療肌營養不良的方法
ZA201700607B (en) Laundry treatment apparatus
ZA201700608B (en) Laundry treatment apparatus
IL257691A (en) A method for treating cancer
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1254258A1 (zh) 使用阿吡莫德治療癌症的方法
ZA201700613B (en) Laundry treatment apparatus
ZA201700611B (en) Laundry treatment apparatus
GB2567616B (en) Treatment method
IL272791A (en) Methods for treating muscular dystrophy
EP3317453A4 (fr) Appareil de traitement de linge
EP3265599A4 (fr) Appareil de traitement de linge
ZA201700668B (en) Laundry treatment apparatus
GB2571601B (en) Treatment method
ZA201700609B (en) Laundry treatment apparatus
EP3294943A4 (fr) Appareil de traitement de linge
ZA201700610B (en) Laundry treatment apparatus
ZA201700612B (en) Laundry treatment apparatus
EP3317451A4 (fr) Appareil de traitement du linge
SG11202001806TA (en) Treatment method
IL259178A (en) Methods for treating muscular dystrophy
ZA201700614B (en) Laundry treatment apparatus
IL254336A0 (en) A new treatment method